Carisma Therapeutics, Inc.

As of September 30, 2025, Carisma Therapeutics, Inc. carries a market capitalization of 11.45M, placing it among publicly traded companies globally. Its enterprise value stands at 9.43M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2025, Carisma Therapeutics, Inc. has 41.79M shares outstanding.

As of September 30, 2025, Carisma Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 1.42. The price-to-sales ratio is 0.22, and the price-to-book ratio stands at -13.21.

As of September 30, 2025, Carisma Therapeutics, Inc. trades at an EV/EBITDA multiple of 0.77 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 0.87 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 9.43M versus a market cap of 11.45M, with the gap driven by net debt and cash on the balance sheet.

As of September 30, 2025, Carisma Therapeutics, Inc. maintains a current ratio of 0.86, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended September 30, 2025. Return on assets (ROA) stands at 33.09, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is negative at -203.23, pointing to unprofitable operations over the period. The company generates approximately 1.14M in revenue per employee across its workforce of 46.00, a quick read on workforce productivity versus industry peers.

As of the close on October 21, 2026, Carisma Therapeutics, Inc.'s stock has declined approximately 99.47% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.02.

Over the twelve months ended September 30, 2025, Carisma Therapeutics, Inc. generated 52.63M in revenue and converted that into 8.04M in net income, yielding earnings per share of 0.19. EBITDA reached 12.18M, while operating income came in at 10.85M.

As of September 30, 2025, Carisma Therapeutics, Inc. holds 2.78M in cash and equivalents against 762,000.00 in total debt, resulting in a net debt position of -2.78M. Total book value stands at -867,000.00, with working capital of -942,000.00 providing operational flexibility.

Carisma Therapeutics, Inc. produced -22.41M in operating cash flow over the twelve months ended September 30, 2025. After subtracting - - in capital expenditures, free cash flow totaled -22.41M - equivalent to -0.54 per share.

These figures cover the twelve months ended September 30, 2025. The operating margin of 20.61 and net profit margin of 15.28 provide insight into operational efficiency.

These figures cover the twelve months ended September 30, 2025. Free cash flow yield is negative at -195.65: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 20.75, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Carisma Therapeutics, Inc. shareholders.

Carisma Therapeutics, Inc.'s most recent stock split took place on March 8, 2023 with a 20:1 split ratio.

As of September 30, 2025, Carisma Therapeutics, Inc. has an Altman Z-Score of -45.54, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.